Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Patrice Hugo, Ph.D.
Immunology; Chief Scientific Officer

Dr. Hugo brings more than 25 years of senior scientific leadership experience with extensive management expertise in laboratory operations applied to diagnostics, therapeutic targets and clinical trials. Most recently, Dr. Hugo was Associate vice president and chief scientist at LabCorp/Covance. He has held several other senior leadership positions at companies including Clearstone Central Laboratories, Caprion and PROCREA BioSciences. A noted industry expert, Dr. Hugo has more than 75 scientific publications in internationally renowned journals. He also is active in a number of industry organizations, including his role on the Board of Directors for the non-for-profit Personalized Medicine Partnership for Cancer in Quebec, Warnex, offering analytical and bioanalytical services and his role as a Steering Committee Member for the Biomarker Factory.

Dr. Hugo obtained his Ph.D. at McGill University and completed five years of post- doctoral fellowship at the Walter Elisa Hall Institute in Australia, and Howard Hughes Medical Institute in Denver, Colorado.

Daniel Buck
In Vitro Diagnostics

Dan Buck is the director of scientific IVD alliance management for Q2 Solutions. His primary responsibilities include providing a solution-driven approach for IVD manufacturers for their device development projects as well as managing and strengthening strategic alliances with key Q2 Solutions’ IVD partners. Dan has over 20 years in the pathology and clinical laboratory industry, with 10 years specifically devoted to the development of IVD and CDx studies.

He received his BA in biological anthropology and anatomy from Duke University and earned an MBA from Boston University and an MPH from Yale University.

Marc Edwards, MD, MBA, FCAP, FASCP
Medical Affairs

Dr. Edwards is the senior medical director, North America, for the Q2 Solutions Laboratory located in Valencia, CA, and a medical advisor to the medical and scientific affairs teams of Q2 Solutions. He has 25 years of experience in the pathology and clinical laboratory, having supported the global pharmaceutical drug development industry from central laboratories providing laboratory, pathology, and biomarker testing services.

He received a BA in Chemistry from Austin College, a Medical Degree from Baylor College of Medicine, and an MBA at the University of Dallas. He did his residency training at The University of Texas Southwestern Medical Center in Dallas, Texas in an accredited AP/CP 5-year Pathology Residency. He is a Board Certified Clinical and Anatomic Pathologist.

Wendell Jones, Ph.D.

Dr. Jones is currently principal bioinformaticist and scientific advisor at Q2 Solutions genomics, where he conducts collaborative scientific research with clients in multiple areas, especially in oncology and immuno-oncology. Dr. Jones has over 15 years of experience in advanced genomic technologies and 20 years of experience in scientific and technology leadership positions, including serving as vice president of statistics and bioinformatics at Expression Analysis, Inc (EA) and chief scientific officer at Reliametrics, a Nortel Networks business unit. His background includes leading the analysis, development and validation of the bioinformatic and computational systems that process complex genomic assays, including next generation sequencing assays, evaluating new and emerging genomic technologies, and developing bioinformatic implementation strategies. He consults with clients and provides thought leadership in industry and public consortiums involved in genomic science and measurement. Dr. Jones serves on the Board of Directors as vice president of the new MAQC Society, and is currently participating in the U.S. Food and Drug Administration (FDA)-led Sequencing Quality Control 2 (SEQC2) consortium which is investigating best-practice methods for variant calling in DNA sequencing studies. He has held leadership roles in the MAQC, MAQC-II, and SEQC consortiums.

He has authored over 40 peer-reviewed publications and has presented at numerous scientific meetings and industry conferences and consortium workshops. Dr. Jones also serves as Adjunct Assistant Professor in the School of Medicine (Dept. of Pathology and Laboratory Medicine) at the University of North Carolina at Chapel Hill.

Dr. Jones obtained a BS, mathematics at Furman University, and earned an MS in math sciences, and a Ph.D in ath sciences (statistics emphasis) at Clemson University.

Ayaskant Pany, MD
Tropical Diseases/Microbiology

Dr. Pany is the sr. medical laboratory director for the Q2 Solutions Laboratories located at Edinburgh, UK & at Centurion, South Africa. He also serves as the scientific advisor for microbiology/tropical diseases as part of the medical and scientific affairs teams of Q2 Solutions. His primary responsibilities include scientific and technical management of the laboratories and its employees, and overseeing developmental activities for TB and microbiology at Q2 Solutions. Previously, Dr. Pany worked at Quintiles Clinical Trials Laboratory, Mumbai, and was in charge of the setting up and operation of bacteriology/molecular biology and mycobacteriology laboratories at Mumbai and Centurion facilities, respectively. He was a research scientist and coordinator for R&D services at the R&D Division (advanced genomics, proteomics and molecular biology) of Super Religare Laboratories Ltd., Mumbai, and as lecturer, Mycobacteriology Section, Department of Microbiology, at St. John’s National Academy of Health Sciences, Bangalore. Dr. Pany has more than 17 years of experience in the medical field in various capacities – scientist, academician, clinician and surgeon - with 7 years within the clinical trial diagnostic industry. His areas of special interest are infectious diseases clinical trials especially tuberculosis, laboratory management, biosafety, assay development and diagnostics. He has presented and published original research and reviews in reputed conferences and journals. He also served as a College of American Pathologists (CAP) Inspector in the fields of microbiology, immunology and molecular biology.

Dr. Pany has an MD in microbiology from Bangalore Medical College and Research Institute and an MBBS from MKCG Medical College, Berhampur, Odisha. He holds a life membership of Indian Association of Medical Microbiologists (IAMM) and is also registered as a Professional Natural Scientist with the South African Council for Natural Scientific Professions (SACNASP).

Joseph Sebastian, Ph.D.
Infectious Diseases

Dr. Joe Sebastian is the scientific advisor for infectious diseases at Q2 Solutions. Most recently, he was associate vice president and national discipline director for molecular infectious diseases at LabCorp. Dr. Sebastian has more than 18 years of scientific leadership experience with extensive management expertise in laboratory operations, report approvals and validation applied to diagnostics and clinical trials, especially in infectious diseases area. He has more than 30 scientific publications in internationally renowned journals and more than 35 scientific presentations at major national meetings. He is also a Fellow of the National Academy of Clinical Chemists.

Dr. Sebastian obtained his Ph.D. in biochemistry at Washington State University and completed post-doctoral fellowships in DNA repair and hormonal carcinogenesis at the University of North Carolina at Chapel Hill and NIEHS/NIH at RTP, NC.

Jian Wang
Precision Medicine Software and Technologies; CEO, BioFortis, Inc

Dr. Wang is the CEO of BioFortis, the precision medicine and technology solutions offering, and a Q2 Solutions company. For more than 20 years, Dr. Wang developed several software products with pharmaceutical customers, government agencies, and academia. He has deep knowledge in the rapidly evolving field of precision medicine and its associated biomarker-driven clinical trials, and strives to bring precision medicine technology solutions to researchers to help solve real-world health problems.

Dr. Jian Wang received his Ph.D. in Bioengineering from the University of Washington.

Alan Wookey
Companion Diagnostics, Oncology

Alan Wookey is the global science lead for companion diagnostics, and the scientific advisor for oncology. He leads business development and scientific strategy for the companion diagnostics and oncology service offerings. He also provides expert consultation in a number of areas including science and technologies, regulatory and management. Prior to joining Q2 Solutions, he served as director and head of the oncology biomarker group at AstraZeneca where he initiated the company’s personalized medicine and pharmacogenetics efforts, as well as its clinical biomarkers group. During his 20+year career, Alan also served as associate vice president, global head of companion siagnostics, of LabCorp Clinical Trials (now Covance).

Alan earned Bachelor of Science degrees in life sciences and microbiology from the University of Liverpool, and a Post Graduate Diploma in management studies from Manchester Metropolitan University.

Michael Brown, Ph.D.
Immunogenicity/Anti-Drug Antibody, Large Molecule PK

Dr. Brown is the immunoanalytical scientific director and site lead for Q2 Solutions. He is responsible for a broad range of oversight of immunoanalytical laboratory operations in Marietta, Georgia, as well as helping to lead and guide our innovation, technology and scientific execution of work in the field of large molecule bioanalysis.

Most recently, Dr. Brown served as managing director and site head of ICON Bioanalytical Laboratories, where he was responsible for the implementation of scientific and organizational quality for regulated bioanalysis. He brings more than 20 years of experience in the contract research organization and life science sector, with the last 10 years holding positions of increasing responsibility in bioanalytical and immunoassay operations at ICON.

Dr. Brown earned a Ph.D. in microbiology and immunology from the State University of New York (SUNY) Health Science Center at Syracuse.

Roger Buchanan, Ph.D.
Safety Testing

Dr. Buchanan is a scientific advisor to the medical and scientific affairs teams of Q2 Solutions. Previously, Roger was laboratory director of a central clinical trials laboratory for 22 years with Quintiles. Under his leadership, in 1996 the laboratory was one of the first in Europe to gain College of American Pathologists accreditation. Prior to that, he trained and practiced as a clinical biochemist at the Royal Infirmary and Yorkhill Children’s Hospital, Glasgow. He worked for in a pharma clinical pathology laboratory servicing Pre-Clinical and Phase 1 studies and performing research into the mechanisms of toxicity, both in-vivo and in-vitro. He has formed lasting relationships with medical and scientific teams throughout the clinical trials industry.

Dr. Buchanan studied biochemistry and completed his PhD at St Andrew’s University, Scotland.

Mark Edinger
Flow Cytometry

Mark Edinger is the scientific advisor for flow cytometry at Q2 Solutions, and is responsible for flow cytometry assay design and implementation. He works with both the Translational Biomarkers Laboratory to develop assays and the Global Cytometry Group to produce assays, and he is the architect of the systems and workflows used in Q2 Solutions’ flow cytometry assay development and production laboratories. Mark joined Quintiles in 2012 and was part of a collaboration which introduced the quantitative standardization of flow cytometers, along with other state of the art practices, making Quintiles flow laboratories the first to offer this level of instrument standardization anywhere in the world. Previously, he worked at Becton Dickinson (BD) where he founded the Technical Applications Group, and later the R&D Systems Validation Laboratory. While at BD, Mark worked with scientists at Amgen to develop the whole blood phosphoprotein lysing buffer that is now used daily in laboratories throughout the world. Mark began his career at the Cleveland Clinic Foundation, a preeminent medical institution, where he pioneered flow cytometry in the late 1970s, building both clinical and research core flow cytometry laboratories. While there, he developed many of the techniques and assays employed today for clinical practice and academic research. During this time, Mark also was a consultant for BD Immunocytometry Systems and participated in clinical trials of new BD products.

Mark graduated from Case Western Reserve University with a Bachelor of Science degree in biology.

Wayne R. Hogrefe, Ph.D

Dr. Hogrefe is the vice president of the vaccine unit at Q2 Solutions, where he has had overall business development responsibilities for the past ten years. Prior to his current role, he served multiple capacities in the reference laboratory and in vitro diagnostics business units of Focus Diagnostics, including director of Immunology, Laboratory Operations, Research and Development, and Technical Services and Scientific Affairs. Additionally, he is a diplomat of the American Board of Medical Laboratory Immunology. He has research and assay development experience in immunoassays for vaccine responses, vector-borne diseases, viral pathogens and emerging pathogens. These activities led to several patents and more than 30 peer-reviewed publications.

Dr. Hogrefe received his Ph.D. in Experimental Pathology at Case Western Reserve University.

Patrick Hurban, Ph.D.

Dr. Hurban is senior director and global head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes.

Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.

Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.

J. Matthew Hutzler, Ph.D.

Dr. Hutzler is the director of In Vitro Metabolism at Q2 Solutions. Previously, he was a DMPK project lead in drug discovery for five years at Boehringer-Ingelheim Pharmaceuticals, where he worked on several project teams supporting inflammation and atherosclerosis therapeutic areas. Dr. Hutzler also held a similar position at Pfizer Inc. (St. Louis) for over five years, initially helping build an in vitro core lab. With over 15 years of experience in the drug metabolism field, his ADME research has focused on characterizing atypical enzyme kinetics for cytochrome P450 enzymes, structure-activity relationships for inhibition of CYP2D6, mechanistic understanding of inhibition of cytochrome P450 enzymes, extrapolation of in vitro metabolism data for human clearance and pharmacokinetic predictions, understanding species differences and variability of aldehyde oxidase activity using hepatocytes, and most recently, investigating novel in vitro models to address slowly metabolized drug molecules. He has published over 30 peer-reviewed articles in high impact journals and three book chapters.

Dr. Hutzler earned his Ph.D. in pharmaceutical sciences from West Virginia University under the direction of Dr. Timothy S. Tracy and completed a post-doctoral fellowship at Pharmacia with Dr. Larry Wienkers.

Radha Krishnan, MD
Anatomic Pathology

Dr. Krishnan is chief pathologist at Q2 Solutions. In this role, and in collaboration with the company’s chief scientific officer and chief operating officer, she defines the plan for global anatomic pathology (AP) service offerings, including instrumentation, technician and pathologists. Additionally, she serves as the scientific advisor for AP services, such as immunohistochemistry (IHC), In-Situ Hybridization (ISH) hematopathology and cytology. This includes the supervision of all assay validation, Pathologist and staff training, proficiency testing, the review and approval of related SOPs, and validations to ensure global harmonization of AP laboratory testing in accordance with applicable regulations governing clinical laboratories.

Dr. Krishnan has more than 22 years of post-specialization experience, with the last seven years in senior leadership roles within Quintiles and Q2 Solutions, including the senior medical director and head of AP for Europe and Asia. Prior to Quintiles, Dr. Krishnan worked as a consultant Pathologist in tertiary referral hospitals and cancer centers and specialized in tumor pathology. She has also been in the academia as an Associate professor in Pathology in the Faculty of Medicine at the University Technology MARA in Malaysia, and a lecturer in Pathology at the International Medical University in Kuala Lumpur.

Dr. Krishnan obtained her Bachelor of Medicine, Bachelor of Surgery (M.B.B.S) and her Doctorate in Medicine (M.D., Pathology) from the University of Madras in India. She is also a Member of the International Academy of Cytology (MIAC).

Steven Lobel, PhD, D-ABMLI, MBA, FACB
Clinical Immunology, Pediatric/Endocrinology

Dr. Lobel is the senior director of Q2 Solutions Medical Laboratories. In this role, he leads medical and scientific aspects of clinical laboratory testing for chemistry, urinalysis, hematology, coagulation, flow cytometry, PBMC processing, microbiology, molecular pathology, automated immunoassays, biomarker testing and anatomic pathology. In addition, he is the scientific lead for pediatric and endocrinology studies.

Dr. Lobel has more than 35 years of experience in the medical and scientific realm within academia, hospital, and central and reference laboratories. He is board certified by the American Board of Medical Laboratory Immunology (D-ABMLI) and as such is approved to direct a CLIA certified laboratory. Dr. Lobel also is board certified by the American Academy of Microbiology and is an elected fellow of the National Academy of Clinical Biochemistry (FACB). He has authored more than 50 peer-reviewed publications, is on the editorial board for clinical and vaccine immunology, and is the recipient of several research grants and awards.

Dr. Lobel earned a Bachelor’s degree in microbiology from University of Texas at Austin and a Masters and Ph.D. in immunology at the School of Medicine at State University of New York at Buffalo. In 1977, he earned a Lady Davis Fellowship to perform post-doctoral research at the Hubert H. Humphrey Center for Experimental Medicine at Hadassah Medical Center in Jerusalem, Israel.  

Stephen Lowes, Ph.D.
Small Molecule PK

Dr. Lowes is a senior scientific director for small molecule and pharmacokinetics, where he leads the scientific disciplines around LC/MS bioanalysis for both small molecule and biomolecule applications including biomarker assays. Previously, he was an executive management scientific leader of Advion BioServices. In 1995 Dr. Lowes joined the CRO group that became Advion and focused his career on regulated bioanalysis with particular emphasis on LC/MS. He has remained very connected on regulatory developments in bioanalysis and is a founding member of the Global Bioanalysis Consortium (GBC) and a past-chair of the AAPS Bioanalytical Focus Group. Dr. Lowes started his industrial career at VG Biotech in the UK that became the LC/MS instrument entity of Waters Corporation. He has more than 40 peer reviewed publications on bioanalysis and is a frequent speaker at national and international conferences.

Dr. Lowes earned his Ph.D. in analytical chemistry from the Open University, United Kingdom.

Nirali M. Patel, MD
Molecular Genetic Pathology

Dr. Patel is the medical director and director of pathology at the Q2 Solutions genomics laboratory in Morrisville NC. She has been actively involved in development of clinical molecular assays and incorporating novel molecular testing into clinical trials throughout her career. She is active in multiple national organizations, previously serving on the board of directors for the Association of Molecular Pathology and giving talks at multiple national pathology and personalized medicine conferences. Dr. Patel is board certified in anatomic, clinical, and molecular genetic pathology.

Dr. Patel received a BS in biology and MD from the University of Miami. She did an AP/CP residency at the University of Chicago (NorthShore) and fellowship at the University of North Carolina, where she continues to serve as an adjunct professor.